About Lymphangioleiomyomatosis
Lymphangioleiomyomatosis is a rare, slowly progressive cystic lung disease caused by mutations in the TSC1 or TSC2 genes, leading to abnormal smooth muscle-like cell proliferation in the lungs. It almost exclusively affects women and may occur sporadically or in association with tuberous sclerosis complex. Over time, the cystic destruction of lung tissue results in declining lung function and, in some cases, respiratory failure.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Lymphangioleiomyomatosis trials.
Trials often require confirmed diagnosis via HRCT showing bilateral pulmonary cysts plus serum VEGF-D elevation or TSC mutation; ensure documentation is up to date.
Many studies exclude women who are pregnant or breastfeeding; clarify reproductive status before screening.
Baseline pulmonary function tests (FEV1, DLCO) are key eligibility metrics; obtain recent spirometry within study-specified windows.
Patient Resources
Find recruiting Lymphangioleiomyomatosis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Lymphangioleiomyomatosis. Updated daily.